Results of lumbar transforaminal epidural steroid injections based on the physician referral source.

Background

Many patients who receive lumbosacral transforaminal epidural steroid injections (TFESIs) are referred for the injection from a physician who does not perform the procedure.

Purpose

To compare success rates of fluoroscopically guided lumbosacral TFESIs in patients who had a clinical evaluation and recommendation for the injection by a fellowship-trained spine specialist who routinely performs ESIs (Group A), vs those who had a clinical evaluation by a fellowship-trained spine specialist who referred the patient for the procedure to be done by a different physician (Group B).

Study design/setting

Retrospective, observational, in vivo study of consecutive patients. Patient.

Sample

Patients undergoing lumbosacral TFESIs at a single outpatient academic spine center. Outcome.

Measures

Numeric Rating Scale (NRS) pain score improvement.

Methods

Current procedural terminology (CPT) codes were used to search all consecutive patients who received a lumbosacral TFESI between September 2019 and September 2020. All patients with pre- and post-injection NRS pain scores within 60 days of the injection were included in the analysis.

Results

A total of 230 TFESIs were analyzed, 151 in Group A, and 79 in Group B. The primary outcome was defined as > 50% improvement in the NRS pain score. 39% [95% CI: 33, 45%] of all patients who received a lumbosacral TFESI achieved a successful outcome. There were better results in Group A with a 47% [95% CI: 39, 55%] success rate compared to a 23% [95% CI: 14, 32%] success rate in Group B. Group A also had a higher proportion of patients who achieved at least 80% pain relief (26% [95% CI: 19, 33%]) compared to Group B (10% [95% CI: 3, 17%]). History of prior surgery did not significantly affect outcomes.

Conclusion

This retrospective study demonstrated a higher success rate from lumbosacral TFESIs when patients were referred for the injection by a physician who performs ESIs.

Informations de copyright

© 2022 The Authors.

Déclaration de conflit d'intérêts

The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Josh Levin reports a relationship with Scilex Pharmaceuticals that includes: consulting or advisory. Matthew Smuck reports a relationship with Sollis Therapeutics that includes: consulting or advisory. Matthew Smuck reports a relationship with Spine Biopharma that includes: board membership and consulting or advisory. Matthew Smuck reports a relationship with Relievant Medsystems that includes: funding grants.